Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Mar 6;9(4):222–229. doi: 10.1002/psp4.12498

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 AstraZeneca. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Dose response of UGE (g/day) for type 2 diabetes mellitus patients treated with dapagliflozin (red), canagliflozin (blue), or empagliflozin (green). Model‐predicted UGE dose response for (a) the in situ scenario using the median MPG and eGFR calculated from all cohorts for each drug and (b) the normalized scenario in which the dose responses are based on the median MPG and eGFR calculated based on the pooled data set for all three drugs. Symbols, clinical data; curves, model‐predicted dose response. eGFR, estimated glomerular filtration rate; MPG, mean daily plasma glucose; UGE, urinary glucose excretion.